Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8089530 | 0.87 | MEN1 (0.51) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL9253579 | 0.84 | NPC1 (0.50) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL30542256 | 0.83 | CES2 (0.68) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL27512587 | 0.81 | NPC1 (0.66) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL9102 | 0.80 | CES2 (0.69) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7953 | 0.80 | CES2 (0.69) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24050798 | 0.80 | CES2 (0.58) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL9647505 | 0.80 | CES2 (0.89) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL755443 | 0.80 | MEN1 (0.69) | CES2CES1NPC1RAB9APARP1 | |
| SCHEMBL12304002 | 0.80 | CES2 (0.58) | CES2CES1NPC1RAB9APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | claimed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | claimed |
| CN-113166759-B | Chemically modified RNAi constructs and uses thereof | 美国安进公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240084301-A1 | RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION | AMGEN INC. (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024026258-A2 | RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION | AMGEN INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4196584-A2 | RNAI CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | Amgen Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116194119-A | RNAi constructs and methods for inhibiting MARC1 expression | 美国安进公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230078200-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION | AMGEN INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2022036126-A2 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | AMGEN INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220049252-A1 | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF | AMGEN INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047621-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | AMGEN INC. (US) | 2022-02-17 | — | — | US | disclosed |
| EP-0420872-A4 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | — | 1992-10-21 | — | — | EP | disclosed |
| US-5089400-A | Recombinant DNA which produces lymphoblastoid interferon-like polypeptides, useful as immunomodulators | CIBA-GEIGY CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-5021550-A | Method for preventing deletion sequences in solid phase synthesis | THOMAS JEFFERSON UNIVERSITY (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0076489-B1 | DEOXYRIBONUCLEIC ACIDS, RECOMBINANT DEOXYRIBONUCLEIC ACIDS, HOSTS CONTAINING THEM, POLYPEPTIDES AND PROCESS FOR THEIR PRODUCTION | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| US-4859768-A | Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0100561-B1 | YEAST HYBRID VECTORS AND THEIR USE FOR THE PRODUCTION OF POLYPEPTIDES | CIBA-GEIGY AG (CH) | 1989-05-31 | — | — | EP | disclosed |
| EP-0100561-A1 | Yeast hybrid vectors and their use for the production of polypeptides | CIBA-GEIGY AG (CH) | 1984-02-15 | — | — | EP | disclosed |
| EP-0076489-A2 | Deoxyribonucleic acids, recombinant deoxyribonucleic acids, hosts containing them, polypeptides and process for their production | CIBA-GEIGY AG (CH) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | CES2 3735/4885CES1 3222/4885NPC1 3486/4885 |
| US-20220047621-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | MARCKS, FABP1, MFAP1 | CES2 3514/4885CES1 26/4885NPC1 230/4885 |
| US-20230078200-A1 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION | LPCAT1, LDLR, LPCAT3 | CES2 2992/4885CES1 807/4885NPC1 165/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | CES2 3735/4885CES1 3222/4885NPC1 3486/4885 |
| US-20220049252-A1 | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF | RNMT, RTCB, RNASE1 | CES2 1904/4885CES1 1402/4885NPC1 606/4885 |
| US-20240084301-A1 | RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION | FAM83A, FABP3, FABP1 | CES2 3097/4885CES1 192/4885NPC1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.